真实世界中水痘疫苗有效性:一项匹配病例对照研究
基于北京市朝阳区2017至2021年1-14岁临床诊断水痘病例的1:2匹配病例对照研究,共纳入2528例病例和5056例对照,采用条件logistic回归评估不同接种状态下的疫苗有效性。研究发现调整末次接种时间后,2剂较1剂的增量疫苗有效性为49.6%(95%CI 38.8-58.6),1剂疫苗有效性93.9% vs 88.0%;12-17月龄接种首剂者风险低于18-23月龄接种者。
要点
- 比较不同接种状态亚组疫苗有效性时需调整末次接种时间。
- 2剂较1剂增量疫苗有效性为49.6%(95%CI 38.8-58.6)。
- 首剂应尽早于出生后第2年接种,第2剂可提高疫苗有效性。
核心结论
- 比较不同接种状态亚组的疫苗有效性时,应调整末次接种时间。
- 水痘疫苗首剂应尽早于出生后第2年接种,第2剂可提高疫苗有效性。
研究设计与样本
- 基于人群监测平台数据开展1:2匹配病例对照研究。
- 病例为北京市朝阳区2017至2021年发病、1-14岁临床诊断水痘病例。
- 对照按出生日期(±1个月)、性别和居住地匹配。
- 接种数据来自北京市儿童免疫规划信息管理系统。
- 采用含或不含交互项的条件logistic回归模型评估不同接种状态的疫苗有效性。
主要发现
- 共纳入2528例病例和5056例对照。
- 是否调整末次接种时间对亚组间疫苗有效性比较有实质性影响。
- 调整末次接种时间后,2剂较1剂的增量疫苗有效性为49.6%(95%CI 38.8-58.6),1剂疫苗有效性93.9% vs 88.0%。
- 接种1剂儿童中,18-23月龄接种者患水痘风险为12-17月龄接种者的1.382倍(95%CI 1.084-1.762)。
- 接种间隔小于1年、2年和3年的疫苗有效性分别高于间隔6年者(P < 0.05)。
临床怎么用
- 作者认为比较不同接种状态亚组的疫苗有效性时应调整末次接种时间。
- 作者认为水痘疫苗首剂应尽早于出生后第2年接种。
- 作者认为第2剂可提高疫苗有效性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Universal varicella vaccination has been introduced in many countries, but there are a number of important differences in their vaccination strategies. It is essential to establish a vaccination program that can maximize the benefits of varicella vaccine, but there is a lack of comprehensive research on the effectiveness of varicella vaccine in different vaccination status. METHODS: Using data from population-based surveillance platforms we conducted a 1:2 matched case-control study. The cases were clinically diagnosed varicella with onset from 2017 to 2021, 1-14 years old in Chaoyang District, Beijing. The controls were matched according to date of birth (±1 month), sex and residence. The vaccination data of the subjects were obtained from the Childhood Immunization Information Management System in Beijing. Using conditional logistic regression models with or without interaction terms, we evaluated the effectiveness of varicella vaccine in different vaccination status. RESULTS: A total of 2528 cases and 5056 controls were enrolled. This study found that whether the time since last vaccination was adjusted had a substantial effect on the comparing vaccine effectiveness (VE) between subgroups. After adjustment for the time since last vaccination, 1) the incremental VE of 2-dose was 49.6 % (95 % Confidence Interval [CI], 38.8-58.6) compared with 1-dose (93.9 % vs. 88.0 %); 2) Among children who received one dose, the risk of chickenpox in children vaccinated at 18-23 months was 1.382 (95 %CI, 1.084-1.762) times that in children vaccinated at 12-17 months. 3) the VE with less than one, two, and three year intervals is higher than that with six-year-intervals (P < 0.05), respectively. CONCLUSIONS: When comparing VE between subgroups of different vaccination status, the time since last vaccination should be adjusted. The first dose of varicella vaccine should be given as early as the second year of life, and the second dose can improve vaccine effectiveness.
引用
- Liu F, Li Z, Wang H, et al. Effectiveness of the varicella vaccine in the real world, a matched case-control study. Vaccine. 2024. PMID: 38734496. doi:10.1016/j.vaccine.2024.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。